12
Participants
Start Date
December 31, 2011
Primary Completion Date
March 31, 2012
Study Completion Date
June 30, 2012
RhuDex
"Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions."
Quotient Clinical, Ruddington
Lead Sponsor
MediGene
INDUSTRY